Annual report pursuant to Section 13 and 15(d)

Fair Value - Obligations for Each Relevant Transaction (Details)

v3.24.1
Fair Value - Obligations for Each Relevant Transaction (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Business Acquisition [Line Items]    
Contingent Consideration Payable $ 0 $ 322,385
Bayon | Successful completion of Phase 2    
Business Acquisition [Line Items]    
Contingent Consideration Payable 1,000,000.0  
Bayon | Successful completion of Phase 3    
Business Acquisition [Line Items]    
Contingent Consideration Payable 4,000,000.0  
Bayon | FDA approval    
Business Acquisition [Line Items]    
Contingent Consideration Payable 1,700,000  
Jade | FDA approval    
Business Acquisition [Line Items]    
Contingent Consideration Payable 2,200,000  
Panoptes | FDA approval    
Business Acquisition [Line Items]    
Contingent Consideration Payable 4,800,000  
Panoptes | Beginning of Phase 3    
Business Acquisition [Line Items]    
Contingent Consideration Payable $ 4,800,000